Zhang Wen-Jun, Chen Dingyi
Department of Rehabilitation Medicine, The Second Affiliated Hospital, Nanchang University, Jiangxi Medical college, Nanchang, China.
Emergency department, The Second Affiliated Hospital, Nanchang University, Jiangxi Medical college, Nanchang, China.
Front Pharmacol. 2024 Nov 29;15:1483716. doi: 10.3389/fphar.2024.1483716. eCollection 2024.
Tumors can invade, compress, and damage nerves, leading to persistent pain and seriously affecting the quality of life of patients. However, their treatment is challenging. Sensitization of peripheral receptors, abnormal activity of primary sensory neurons, activation of glial cells, enhanced inflammatory responses, and sensory information transmission contribute towards cancer pain. Therefore, considerable attention has been paid to exploring prospective methods to inhibit the occurrence of these factors and relieve cancer pain. Studies on different types of pains have revealed that the transplantation of functionally active cells into the host has the pharmacological effect of producing analgesia. Mesenchymal stem cells (MSCs) can act as small active pumps to reduce the expression of pain-related molecules and produce analgesic effects. Moreover, MSCs can establish complex communication networks with non-tumor and cancer cells in the microenvironment, interact with each other, and can be used as destinations for inflammation and tumor sites, affecting their potential for invasion and metastasis. This emphasizes the key role of MSCs in cancer and pain management. The pain relief mechanisms of MSCs include neuronutrition, neural protection, neural network reconstruction, immune regulation, and improvement of the inflammatory microenvironment around the nerve injury. All of these are beneficial for the recovery of injured or stimulated nerves and the reconstruction of neural function, and play a role in relieving pain. The pain treatment strategy of cell transplantation is to repair injured nerves and produce analgesic pharmacological properties that are different from those of painkillers and other physiotherapies. Although the therapeutic role of MSCs in cancer and pain is in its early stages, the therapeutic value of MSCs for cancer pain has great prospects. Therefore, in this study, we explored the possible mechanism between MSCs and cancer pain, the potential therapeutic role of therapeutic cells in cancer pain, and some problems and challenges.
肿瘤可侵袭、压迫并损伤神经,导致持续性疼痛,严重影响患者的生活质量。然而,其治疗颇具挑战性。外周感受器的敏化、初级感觉神经元的异常活动、神经胶质细胞的激活、炎症反应增强以及感觉信息传递都与癌痛有关。因此,人们相当关注探索抑制这些因素发生并缓解癌痛的前瞻性方法。对不同类型疼痛的研究表明,将功能活跃的细胞移植到宿主体内具有产生镇痛的药理作用。间充质干细胞(MSCs)可充当小型活性泵,以降低疼痛相关分子的表达并产生镇痛作用。此外,MSCs可在微环境中与非肿瘤细胞和癌细胞建立复杂的通讯网络,相互作用,并可作为炎症和肿瘤部位的靶点,影响其侵袭和转移潜能。这凸显了MSCs在癌症和疼痛管理中的关键作用。MSCs的镇痛机制包括神经营养、神经保护、神经网络重建、免疫调节以及改善神经损伤周围的炎症微环境。所有这些都有利于受损或受刺激神经的恢复以及神经功能的重建,并在缓解疼痛中发挥作用。细胞移植的疼痛治疗策略是修复受损神经,并产生与止痛药和其他物理疗法不同的镇痛药理特性。尽管MSCs在癌症和疼痛方面的治疗作用尚处于早期阶段,但MSCs对癌痛的治疗价值前景广阔。因此,在本研究中,我们探讨了MSCs与癌痛之间的可能机制、治疗性细胞在癌痛中的潜在治疗作用以及一些问题和挑战。
Front Pharmacol. 2024-11-29
Front Cell Dev Biol. 2025-2-21
Neuroscience. 2024-8-30
Stem Cell Res Ther. 2024-7-18
Curr Stem Cell Res Ther. 2024
Front Cell Dev Biol. 2023-4-5